In this study we want to learn more about the factors that affect quality of life for breast cancer survivors. We also want to learn about the common experiences patients face. What we learn in this study could be used in future research to address overlooked challenges for patients in life after treatment.

The purpose of this study is to increase the involvement of black breast cancer patients in clinical research trials and connect these patients with resources.

In this study, we want to understand the experiences of Black women in their journey to a diagnosis of endometrial cancer. Learning more about the diagnosis experience will help us to understand what made it easy or difficult to get their diagnosis. This information will help us to develop a tool to improve the endometrial cancer diagnosis experience.

The purpose of this research study is to better understand, from the perspective of Black patients, whether telemedicine visits make prostate cancer decision making easier or harder. The COVID-19 pandemic made it more difficult for patients to see their doctors, but care could continue by having appointments via a computer or phone, which many prostate cancer doctors used. Whether in person or remote, successfully choosing a treatment for prostate cancer often uses shared decision making (SDM), the process where doctors and patients work together to make decisions that match what matters to patients, but it is unknown whether virtual appointments make discussions better or worse. Other studies have shown that Black patients may be less satisfied with their treatment choices than non-Black patients. Therefore, it is important that we understand how to improve the same quality of care for Black patients.

Have you been recently diagnosed with Diffuse Large B Cell Lymphoma? Are you over 75 years of age? If so, you may be able to take part in a research study looking at the safety of giving a new study drug CC-486 (oral azacitidine) in addition to the standard chemotherapy drug combination used to treat this disease.

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.

To find the safest and most tolerable dose of CAR.B7-H3 T cells to administer in patients with relapsed/refractory platinum-resistant epithelial ovarian cancer.

Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.

Do you have mantle cell lymphoma or other non-Hodgkin lymphoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.